US Bancorp DE Decreases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

US Bancorp DE cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,042 shares of the company’s stock after selling 1,958 shares during the period. US Bancorp DE’s holdings in Vaxcyte were worth $805,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Darwin Global Management Ltd. lifted its holdings in Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after purchasing an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Capital Research Global Investors lifted its holdings in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares in the last quarter. Finally, Avoro Capital Advisors LLC purchased a new position in Vaxcyte in the 1st quarter valued at about $39,278,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on PCVX. Mizuho upped their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. BTIG Research upped their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Jefferies Financial Group upped their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the transaction, the chief executive officer now owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares in the company, valued at $21,968,226. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the transaction, the chief executive officer now owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,464 shares of company stock valued at $12,640,276. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Performance

PCVX opened at $106.67 on Friday. The firm has a 50 day moving average price of $111.56 and a 200 day moving average price of $87.23. The company has a market cap of $13.30 billion, a PE ratio of -23.19 and a beta of 1.01. Vaxcyte, Inc. has a 1 year low of $46.16 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) EPS. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.